-
Research institutions sometimes struggle with retaining experienced IRB members as the workload can be significant and there are so many competing duties and projects for these scientists, professors, bioethicists, and other professionals.
-
-
The 2011 changes to the National Institutes of Health (NIH) Public Health Service (PHS) regulations for reporting investigator conflicts of interest may still be causing confusion for researchers and IRBs.
-
Protocol review consistency is a hot topic as IRBs, research organizations, and investigators struggle with balancing quality and efficiency in the review process.
-
-
-
In this issue: Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.
-
-
Get ready to recommend flu vaccine to your pregnant and postpartum patients. According to the Centers for Disease Control and Prevention (CDC), less than one-fourth of pregnant women in the United States were vaccinated against seasonal influenza during the 2007-08 flu season.
-
Post-marketing surveillance outside the United States of the two FDA-licensed rotavirus vaccines, RotaTeq (Merck, licensed in 2006) and Rotarix (GSK Biologicals, licensed in 2008), have identified a very low but increased risk (1 case/100,000 vaccinated infants) of intussusception following Rotarix vaccination.
